OPKO Health
Market Cap
US$3.0b
Last Updated
2021/01/15 23:47 UTC
Data Sources
Company Financials +
Executive Summary
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Fair value with moderate growth potential.
Similar Companies
Share Price & News
How has OPKO Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OPK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: OPK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
3.4%
OPK
3.5%
US Biotechs
-0.9%
US Market
1 Year Return
191.7%
OPK
36.8%
US Biotechs
19.6%
US Market
Return vs Industry: OPK exceeded the US Biotechs industry which returned 36% over the past year.
Return vs Market: OPK exceeded the US Market which returned 21% over the past year.
Shareholder returns
| OPK | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.4% | 3.5% | -0.9% |
| 30 Day | 1.6% | 6.0% | 3.0% |
| 90 Day | 5.9% | 19.2% | 11.5% |
| 1 Year | 191.7%191.7% | 39.1%36.8% | 22.3%19.6% |
| 3 Year | 1.8%1.8% | 30.5%23.6% | 45.3%35.7% |
| 5 Year | -44.8%-44.8% | 43.7%32.8% | 124.8%99.9% |
Long-Term Price Volatility Vs. Market
How volatile is OPKO Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Insider Buying: The OPKO Health, Inc. (NASDAQ:OPK) Chairman & CEO Just Bought US$1.2m Worth Of Shares2 weeks ago | Simply Wall St
Here's What OPKO Health, Inc.'s (NASDAQ:OPK) Shareholder Ownership Structure Looks Like1 month ago | Simply Wall St
Announcing: OPKO Health (NASDAQ:OPK) Stock Increased An Energizing 207% In The Last YearValuation
Is OPKO Health undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OPK ($4.55) is trading below our estimate of fair value ($15.8)
Significantly Below Fair Value: OPK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OPK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: OPK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OPK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OPK is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (4.3x).
Next Steps
Future Growth
How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
25.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: OPK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OPK's is expected to become profitable in the next 3 years.
Revenue vs Market: OPK's revenue (1.6% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: OPK's revenue (1.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OPKO Health performed over the past 5 years?
-35.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPK is currently unprofitable.
Growing Profit Margin: OPK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OPK is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.
Accelerating Growth: Unable to compare OPK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: OPK has a negative Return on Equity (-7.02%), as it is currently unprofitable.
Next Steps
Financial Health
How is OPKO Health's financial position?
Financial Position Analysis
Short Term Liabilities: OPK's short term assets ($428.1M) exceed its short term liabilities ($335.9M).
Long Term Liabilities: OPK's short term assets ($428.1M) exceed its long term liabilities ($411.6M).
Debt to Equity History and Analysis
Debt Level: OPK's debt to equity ratio (14.5%) is considered satisfactory.
Reducing Debt: OPK's debt to equity ratio has increased from 6.5% to 14.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OPK has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OPK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is OPKO Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OPK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OPK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OPK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.8yrs
Average management tenure
CEO
Phil Frost (84 yo)
13.83yrs
Tenure
US$1,405,200
Compensation
Dr. Phillip Frost, also known as Phil, M.D., Ph.D., has been Chief Executive Officer of Opko Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and General Partner of Frost Philli...
CEO Compensation Analysis
Compensation vs Market: Phil's total compensation ($USD1.41M) is below average for companies of similar size in the US market ($USD4.98M).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 13.83yrs | US$1.41m | 29.02% $ 884.7m | |
| Vice Chairman & Chief Technical Officer | 13.67yrs | US$1.35m | 4.88% $ 148.9m | |
| Senior VP & CFO | 6.83yrs | US$921.20k | 0.027% $ 815.2k | |
| Executive VP of Administration & Director | 13.92yrs | US$1.13m | 0.86% $ 26.2m | |
| Chief Accounting Officer | 0.50yr | no data | 0.000010% $ 304.9 | |
| President of API | no data | no data | no data | |
| Senior Vice President of Pharmaceutical Sales | 4.75yrs | no data | no data | |
| Chief Commercial Officer | 4.67yrs | no data | no data | |
| Senior Vice President of Clinical Research & Development and Medical Affairs | 3.83yrs | no data | no data | |
| Senior VP & Director | 2yrs | no data | 0.011% $ 341.1k | |
| Chief Legal Officer of Bio-Reference Laboratories | no data | no data | no data | |
| President of OPKO Diagnostics | 7.5yrs | no data | no data |
6.8yrs
Average Tenure
63yo
Average Age
Experienced Management: OPK's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 13.83yrs | US$1.41m | 29.02% $ 884.7m | |
| Vice Chairman & Chief Technical Officer | 13.67yrs | US$1.35m | 4.88% $ 148.9m | |
| Executive VP of Administration & Director | 13.92yrs | US$1.13m | 0.86% $ 26.2m | |
| Senior VP & Director | 2yrs | no data | 0.011% $ 341.1k | |
| Lead Independent Director | no data | US$66.50k | 0.041% $ 1.3m | |
| Independent Director & Member of Scientific Advisory Board | 13.83yrs | US$51.00k | 0.030% $ 904.8k | |
| Independent Director | 17.08yrs | US$56.00k | 0.055% $ 1.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 11.75yrs | US$41.00k | 0.0099% $ 302.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.75yrs | US$48.92k | 0.62% $ 18.7m |
13.8yrs
Average Tenure
73yo
Average Age
Experienced Board: OPK's board of directors are seasoned and experienced ( 13.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OPK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
OPKO Health, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OPKO Health, Inc.
- Ticker: OPK
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.049b
- Shares outstanding: 670.00m
- Website: https://www.opko.com
Number of Employees
Location
- OPKO Health, Inc.
- 4400 Biscayne Boulevard
- Miami
- Florida
- 33137
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| XCY | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 1995 |
| OPK | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Nov 1995 |
| OPK * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Nov 1995 |
| OPK | TASE (The Tel-Aviv Stock Exchange) | Yes | Common Stock | IL | ILS | Nov 1995 |
| 0KCS | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Nov 1995 |
Biography
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostic...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/15 23:47 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.